NEWSLETTER OF THE HEMOPHILIA FOUNDATION OF MINNESOTA AND THE DAKOTAS

HEMOPHILIA FOUNDATION OF MINNESOTA/DAKOTAS

Veinline

SUMMER 2022

HFMD MISSION

We dedicate ourselves to advancing the quality of life of individuals and families affected by hemophilia or other bleeding disorders by providing a broad range of services and programs.

Inside this issue:

SUMMER CAMP 2022

We had a great time at the HFMD Summer camp in June, and enjoyed spending time with our campers from all over MN, ND, SD, and IA! For the first time, Camp was held at YMCA Camp Iduhapi in Loretto, MN. Located on a beautiful acreage, Camp is surrounded by forest and prairie, nestled on the shore of the aptly named Lake Independence.

Through a combination of programming, fun activities, and charismatic staff, Iduhapi strives to foster character development, skill building and life-long friendships within their campers. What a great setting to learn more about bleeding disorders, develop self-care skills, and find community!

Truly, nothing can beat the bonds and memories that develop at summer camp, and it is a joy to reminisce about it. So, what did we do?

(continued on page 2)

Summer Camp 2022

(continued from page 1)

We had fun. Each day campers participated in team building games and activities with their cabins in the morning, and then selected from a wide range of activities in the afternoon. Some favorites included horseback riding, the climbing wall, gaga ball, sports, and arts and crafts. With record breaking hot temperatures, swimming in Lake Independence was also popular! Campers enjoyed jumping off the dock, swimming, floating, and playing ball on the waterfront.

We learned. There were daily opportunities to work with HTC clinical staff on skills such as Sub-Q injections using HEMLIBRA practice kits, and self-infusing. Many participated in an education initiative to learn more about their bleeding disorder, earning cool wrist bands for completion of four series of trivia questions and skill demonstrations. Dawn Rusk of Mayo Clinic also led a great girl's focused group one afternoon.

We inspired. Each day, older campers could be found in the health center during prophy time, supporting younger campers through demonstrations, encouragement, and sharing words of wisdom. Continuing a favorite tradition, we recognized the huge milestone of attempting an IV stick for the first time with The Big Stick, campers clapping and cheering one another on. Positive energy and inspiring the next steps to independence was evident in the health center.

We found identity. It is the people who make camp special, and we had a great turnout this year- a combination of first-time campers with those who have attended for many seasons. To recognize this week of camp and the many years to come, we had the goal of determining an official camp name! Campers and staff helped to generate, submit, and vote on names…. and during closing campfire, the voting results were revealed. **We are officially Camp Not-A-Clot!!** A name that is fun, catchy and inclusive of the multiple bleeding disorder diagnoses that we see.

A huge thank you to our campers and staff from Children's MN, Mayo Clinic, M Health Fairview, Sanford Health ND, and Sanford Health SD for making it a great week. We are already looking forward to Camp Not-A-Clot 2023! - By Becca Shaheen

(More fun Camp pictures on page 3!)

Summer Camp 2022 Photos

CAN YOU SOLVE

FOR A DIFFERENT HEMOPHILIA A TREATMENT?

Test your HEMLIBRA knowledge



ACROSS

1. Wine barrel
5. Deep fissures
11. Mideast gulf port
12. District
13. Ripped
14. Familiar with
15. Mean
17. Roost
18. The #1 prescribed prophylaxis for people with hemophilia A without factor VIII inhibitors*

*According to IQVIA claims data from various insurance plan types from April 2020 - May 2021 and accounts for usage in prophylaxis settings in the US.

21. Calendar divs.
22. Regret
23. Banquet hosts (abbr.)
26. International travel necessity
28. Check out the _____ treated bleeds data with HEMLIBRA
31. Number of dosing options HEMLIBRA offers

†Number of people with hemophilia A treated as of October 2021.

32. Small hole in lace cloth
35. Central Plains tribe
36. Melodic
37. Towering
38. Reduce
39. Spanish cheers

DOWN

1. Memorable, as an earworm
2. Devotee
3. Medical fluids
4. Prepare to propose, perhaps
5. PC's "brain"
6. Owns
7. Concert venue
8. See Medication Guide or talk to your doctor about potential _____ effects
9. Winter hrs. in Denver and El Paso
10. HEMLIBRA is the only prophylactic treatment offered this way under the skin
16. Pre-Euro currency in Italy
19. Subway alternative
20. Relax
23. Human
24. New Orleans cuisine
25. Mentally prepares
26. Collared shirts
27. Instagram post
28. Ardent enthusiasm
29. Brontë heroine Jane
30. Old Portuguese coins
33. Opposite of WNW
34. More than_____ thousand patients have been treated with HEMLIBRA worldwide†

SOLUTIONS

Across: 1. cask, 5. chasms, 11. Aden, 12. parish, 13. torn, 14. used to, 15. cruel, 17. nest, 18. HEMLIBRA, 21. yrs, 22. rue, 23. MCs, 26. passport, 28. zero, 31. three, 32. eyelet, 35. Otoe, 36. arose, 37. tall, 38. lessen, 39. oles

Down: 1. catchy, 2. adorer, 3. serums, 4. kneel, 5. CPU, 6. has, 7. arena, 8. side, 9. MSTs, 10. shot, 16. lira, 19. bus, 20. rest, 22. mortal, 24. Creole, 25. steels, 26. polos, 27. photo, 28. zeal, 29. Eyre, 30. Reis, 33. ESE, 34. ten

Discover more at HEMLIBRA.com/answers

INDICATION & IMPORTANT SAFETY INFORMATION

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

- **Thrombotic microangiopathy (TMA),** a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- **Blood clots (thrombotic events),** which may form in blood vessels in your arm, leg, lung, or head

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including **Serious Side Effects.**

HEMLIBRA®
emicizumab-kxwh
injection for subcutaneous use
150 mg/mL

Medication Guide
HEMLIBRA® (hem-lee-bruh)
(emicizumab-kxwh)
injection, for subcutaneous use

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment.

HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:

- **Thrombotic microangiopathy (TMA).** This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
  - confusion
  - weakness
  - swelling of arms and legs
  - yellowing of skin and eyes
  - stomach (abdomen) or back pain
  - nausea or vomiting
  - feeling sick
  - decreased urination
- **Blood clots (thrombotic events).** Blood clots may form in blood vessels in your arm, leg, lung, or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
  - swelling in arms or legs
  - pain or redness in your arms or legs
  - shortness of breath
  - chest pain or tightness
  - fast heart rate
  - cough up blood
  - feel faint
  - headache
  - numbness in your face
  - eye pain or swelling
  - trouble seeing

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

See "**What are the possible side effects of HEMLIBRA?**" for more information about side effects.

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.

HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use HEMLIBRA?

See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

- Use HEMLIBRA exactly as prescribed by your healthcare provider.
- **Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.**
- **You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.**
- HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.
- Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.
- You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.
- If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed dose as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. **Do not** give two doses on the same day to make up for a missed dose.
- HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

What are the possible side effects of HEMLIBRA?

- See "**What is the most important information I should know about HEMLIBRA?**"

The most common side effects of HEMLIBRA include:

- redness, tenderness, warmth, or itching at the site of injection
- headache
- joint pain

These are not all of the possible side effects of HEMLIBRA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store HEMLIBRA?

- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.
- Throw away (dispose of) any unused HEMLIBRA left in the vial.

Keep HEMLIBRA and all medicines out of the reach of children.

General information about the safe and effective use of HEMLIBRA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.

What are the ingredients in HEMLIBRA?

Active ingredient: emicizumab-kxwh

Inactive ingredients: L-arginine, L-histidine, poloxamer 188, and L-aspartic acid.

Manufactured by: Genentech, Inc., A Member of the Roche Group,
1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No. 1048

For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
This Medication Guide has been approved by the U.S. Food and Drug Administration
Revised: 12/2021

HEMLIBRA®
emicizumab-kxwh
injection for subcutaneous use
150 mg/mL

Genentech
A Member of the Roche Group

Have You Been Negatively Impacted by the Accumulator Adjustor from Your Health Care Plan?

Rare diseases including bleeding disorders are very expensive to treat There are affected Minnesota families and individuals who rely on 3rd party assistance to help offset their out-of-pocket costs; which for many hit the maximum of $8,700 for an individual, and $17,400 (in 2022) for a family each and every year.

Now, some health insurance companies have taken aggressive steps to deny families from using out-of-pocket assistance from manufacturers intended to help them. Patients/families have been stunned to find out they still owe money that has already been collected but NOT applied to their maximum out-of-pocket cost calculation. This practice, known as the Accumulator Adjustor is wrong, it is misguided, and it should be banned in Minnesota!

During this 2022 Minnesota legislative session, the HFMD worked very hard to advance Senate File (SF) 2136 which had been introduced by Senator Mary Kunesh inspired from the Arthritis Foundation to ban the Accumulator in Minnesota in 2021 but did not get beyond it's introduction.

HFMD joined the effort in 2022 to help inspire the introduction of its companion bill House File (HF) 3611, and then we managed to get bipartisan authorship on both bills in the House & Senate; thanks to Representative Rena Moran, Rep. Glenn Gruenhagen & Senator Jim Abeler.

With a support letter from 30 patient advocacy groups and momentum moving toward getting the bills advancing to ban the Accumulator Adjustor in MN; HF 3166 got a Commerce Committee hearing in early April and narrowly passed that committee with a 9-8 vote!

Things looked promising at that point with Minnesota poised to become the 14th state to pass this type of bill. Then, as many know, the Minnesota legislature broke down with very little getting done and neither HF 3611 or SF 2136 passed to become law.

But, progress was made in both House & Senate to be in a good position to get the bills passed in 2023.

If you have been affected by the Accumulator, please contact the HFMD at info@hfmd.org to share your story.

One of the few health care related bill that did pass was HF 626 which will move the MN Rare Disease Advisory Council to be housed under the MNCCD (The Minnesota Consortium for Citizens with Disabilities). *By Jim Paist*

Jivi
antihemophilic factor
(recombinant) PEGylated-aucl
LET'S GO

JIVI®
ADYNOVATE®

PK (Pharmacokinetics) Study Data

Talk to your doctor about the study.

Scan the QR code to learn more about PK at **UnderstandingPK.com**

Current Calendar of Events

July 30, 2022……..	SD Education Day Great Plains Zoo, Sioux Falls
August 21, 2022……	Step Out for Bleeding Disorders Walk Harriet Island REGISTER HERE
August 25-27, 2022……	National Hemophilia Foundation, Bleeding Disorders Conference Houston, TX FOR MORE INFO
October 8, 2022……	Women's Event Al & Alma's Charter Cruises, Wayzata, MN
November 11-13, 2022……..	Mayo Clinic Family Event Embassy Suites, Bloomington, MN & Science Museum of MN
November 19, 2022……	HFMD Symposium Eagan Community Center, Eagan, MN

Visit our website at www.hfmd.org/events/ for more information and to register!

HFMD
Hemophilia Foundation of Minnesota/Dakotas
Step Out for Bleeding Disorders

Get your walking shoes ready!
If you haven't already, now's the time to form a team or register as an individual to walk in the 12th Annual Step Out for Bleeding Disorders fundraiser walk.

Sunday, August 21, 2022
Harriet Island Regional Park, St. Paul MN

Click Here for more info and to sign up today!

Scholarships

Each year, the HFMD is honored to award scholarships to students pursuing their post-secondary education.

Applicants must be a resident of MN or SD with an inherited bleeding disorder, seeking treatment at one of our affiliated Hemophilia Treatment Centers.

As part of the application process, students provide information about their education goals, their extracurricular activities and hobbies, work and volunteer history and outstanding achievements. Letters of recommendation from previous or current academic advisors or instructors, as well as one from a friend or co-worker, are also required.

Scholarship applications and more information can be found on the HFMD website under the Programs and Services. Applications for the scholarships are posted in April and must be sent to HFMD by June 1st each year.

The applications for the 2022-23 school year are currently under review. HFMD will mail out acceptance letters to the scholarship recipients mid July. Awarded scholarship funds will be paid directly to the academic institution. If you are one of the students who applied, check your mail in the next few weeks. Good luck!

ADVATE has over 15 years of treatment experience in the real world and provides clinically proven bleed protection* for patients with hemophilia A.[1]

ADVATE
[Antihemophilic Factor (Recombinant)]
REAL LIFE. REAL BLEED PROTECTION.*

AdvateRealLife.com

Prophylaxis with ADVATE prevented bleeds[1]

The ability of ADVATE to treat or prevent bleeds was evaluated in a clinical study using a standard prophylaxis, pharmacokinetic driven prophylaxis, and on-demand treatment.

53 previously treated patients (PTPs) with severe to moderately severe hemophilia A were analyzed. For the first 6 months of the study, patients received on-demand treatment. For the following 12 months of the study, patients received either standard prophylaxis every 48 hours or a pharmacokinetic-driven prophylaxis every 72 hours. The primary goal of the study was to compare annual bleeding rates between those receiving prophylaxis treatment and those receiving treatment on-demand. The number of bleeds per year for the 2 prophylaxis regimens were comparable.

- Those patients experienced a median of 1 overall bleed per year on either prophylaxis treatment vs 44 overall bleeds per year with on-demand treatment.† This represented a 98% reduction in overall bleeds per year.
- Zero bleeds were reported in 42% of patients (22 out of 53 patients) during 12 months on prophylaxis

†Median is the middle number in a group of numbers arranged from lowest to highest.

ADVATE Important Information

What is ADVATE?

- ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called "classic" hemophilia).
- ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Your healthcare provider (HCP) may give you ADVATE when you have surgery.
- ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Who should not use ADVATE?

Do not use ADVATE if you:

- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.

Tell your HCP if you are pregnant or breastfeeding because ADVATE may not be right for you.

What should I tell my HCP before using ADVATE?

Tell your HCP if you:

- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Are breastfeeding. It is not known if ADVATE passes into your milk and if it can harm your baby.

What should I tell my HCP before using ADVATE? (continued)

- Are or become pregnant. It is not known if ADVATE may harm your unborn baby.
- Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

What important information do I need to know about ADVATE?

- You can have an allergic reaction to ADVATE. Call your HCP right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.
- Do not attempt to infuse yourself with ADVATE unless you have been taught by your HCP or hemophilia center.

What else should I know about ADVATE and Hemophilia A?

- Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Talk with your HCP to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

What are possible side effects of ADVATE?

- Side effects that have been reported with ADVATE include: cough, headache, joint swelling/aching, sore throat, fever, itching, unusual taste, dizziness, hematoma, abdominal pain, hot flashes, swelling of legs, diarrhea, chills, runny nose/congestion, nausea/vomiting, sweating, and rash. Tell your HCP about any side effects that bother you or do not go away or if your bleeding does not stop after taking ADVATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Important Facts about ADVATE on the following page and discuss with your HCP.

For Full Prescribing Information, visit www.ADVATE.com.

Reference: 1. ADVATE Prescribing Information.

Takeda

ADVATE
[Antihemophilic Factor (Recombinant)]

Important facts about

ADVATE [Antihemophilic Factor (Recombinant)]

This leaflet summarizes important information about ADVATE. Please read it carefully before using this medicine. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about ADVATE. If you have any questions after reading this, ask your healthcare provider.

What is the most important information I need to know about ADVATE?

Do not attempt to do an infusion to yourself unless you have been taught how by your healthcare provider or hemophilia center.

You must carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing ADVATE so that your treatment will work best for you.

What is ADVATE?

ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called "classic" hemophilia). The product does not contain plasma or albumin. Hemophilia A is an inherited bleeding disorder that prevents blood from clotting normally.

ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A.

Your healthcare provider may give you ADVATE when you have surgery. ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

Who should not use ADVATE?

You should not use ADVATE if you:

- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.

Tell your healthcare provider if you are pregnant or breastfeeding because ADVATE may not be right for you.

How should I use ADVATE?

ADVATE is given directly into the bloodstream.

You may infuse ADVATE at a hemophilia treatment center, at your healthcare provider's office or in your home. You should be trained on how to do infusions by your healthcare provider or hemophilia treatment center. Many people with hemophilia A learn to infuse their ADVATE by themselves or with the help of a family member.

Your healthcare provider will tell you how much ADVATE to use based on your weight, the severity of your hemophilia A, and where you are bleeding.

You may have to have blood tests done after getting ADVATE to be sure that your blood level of factor VIII is high enough to clot your blood.

Call your healthcare provider right away if your bleeding does not stop after taking ADVATE.

What should I tell my healthcare provider before I use ADVATE?

You should tell your healthcare provider if you:

- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Are breastfeeding. It is not known if ADVATE passes into your milk and if it can harm your baby.
- Are pregnant or planning to become pregnant. It is not known if ADVATE may harm your unborn baby.
- Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

What are the possible side effects of ADVATE?

You can have an allergic reaction to ADVATE.

Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

Side effects that have been reported with ADVATE include:

cough	headache	joint swelling/aching
sore throat	fever	itching
unusual taste	dizziness	hematoma
abdominal pain	hot flashes	swelling of legs
diarrhea	chills	runny nose/congestion
nausea/vomiting	sweating	rash

Tell your healthcare provider about any side effects that bother you or do not go away

These are not all the possible side effects with ADVATE. You can ask your healthcare provider for information that is written for healthcare professionals.

What else should I know about ADVATE and Hemophilia A?

Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ADVATE for a condition for which it is not prescribed. Do not share ADVATE with other people, even if they have the same symptoms that you have.

The risk information provided here is not comprehensive. To learn more, talk with your health care provider or pharmacist about ADVATE. The FDA-approved product labeling can be found at www.ADVATE.com or 1-877-825-3327.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

U.S. License No. 2020
Issued: 12/2018

US-ADV-0030v1.0 02/20

Takeda

The HFMD gratefully acknowledges our donors who have given so generously. These are donations received from January 1 - June 30, 2022

Organizational & Business Contributors:

$40,000 and Up
Mayo Foundation for Medical Education & Research

$9,000-$39,999
Bayer HealthCare
M Health Fairview
Takeda

$3,000-$8,999
ARJ Infusion
BioMarin Pharmaceuticals
Children's Hospitals and Clinics of Minnesota
Cigna / Accredo
CSL Behring
CVS Specialty Pharmacy
Genentech
HEMA Biologics
Hemophilia Alliance Foundation
Novo Nordisk
Octapharma
Optum
Sanofi

$1,000-$2,999
Maguire Agency
Pfizer

$500-$999
Deano's Collision
Fu'una Custom Jewelry
Renaissance Charitable Foundation
- *In Honor of Mason Schulte*
Toro Corporation

Up to $499
Alloy Brewing
America's Charities
Blackbaud Giving Fund
Craft & Crew Restaurants
General Store of Minnetonka
Hardshell Fitness
Hope Breakfast Bar
Knights of Columbus
Lanz Electric
MN Timberwolves
MN Vikings
Network for Good
Novel Energy
Off the Hook by Katy
Olive Grove
Rockin' Jump
Sara Biren (author)
St Paul Saints
Summer Lakes Beverages
Surly Brewing
The Nook/Shamrocks
Tis Best Philanthropy
Valleyfair
Youngstedt's Auto Service

Individual Contributors:

$5,000 and Up
Heisel-Kurth, Dr. Margaret & Frank Kurth

$1,000-$4,999
Bremer, Dick & Heidi
O'Brien, Patti & Tim
O'Connell, Jean
Rauenhorst, Rich & Elizabeth
Rauenhorst, Kris & David,
- *In Loving Memory of James Brown*

$500-$999
Clarin, Jason & Jennifer
Kearney, Dr. Susan & Rob Rothaar
Laquere, Michael
Stradtman, Jordan

$200-$499
Abdel, Mark
Becchetti, Chris
Curoe, Sue & Phil
Gollinger, Deirdre
Lees, Mason
Manns, Kris & Joel
Mazepa, Allie
Nelson, Justin
Otto, Melinda
Paist, James
Ravine, Charlie
Rusk, Dawn
Schulte, John & Karen

$100-$199
Barham, Mark
Baumann, Kim & Brad
Gleason, Troy
Hedlund, Todd
Hennen, Edward & Nancy
Holmes, Mike
Ianello-Zimmer, Dena
Kivel, Mary
Klersy-Daniels, Angie
LaBarre, Robert
Lunde, Melissa
Makepeace, Jeff & Annie
Marema, Kristin
Nagel, Bill & Michelle
Osip, Joni
Phillips, Anika
Schmitt, Richard
Schulte, Cole
Tokar, Paul & Mary
Trivedi, Urvish
Wessel, Michael
Wiener, Mark
Wilson, Amy

$50-$99
Benner, Jordan
Chan, Ricky
Colling, Julia
Cordes, Melissa
Geer, Rosemary
Hemann, Josh
Hickman, Janice
Kilroy, Michelle Marie
Kivel, Anne, Nick & Casey
Kunkel, Cody
Murray, Milena & Chris
Naughton, Tyler & Maggie Herrity
Schatz, June
Seeger, Bethany & Bryan Linn
Seeger, Rose
Williams, Jovon & Kevin

(Donors list continued on next page)

The HFMD gratefully acknowledges our donors who have given so generously. These are donations received from January 1 - June 30, 2022

(Donor List continued from previous page)

Up to $49

Ace, Julie
Bearss, Bryan
Dreyer, Mark W.
Germain, Matt, Tresa & Family
Goodale, Doug
Groat, Jeff
Kordosky, Robert
Kunkel, Joe & Lori
Kuper, Lindsey
Lesnar, Jenny
Linder, Kimberlee
Marquez, Amy
Nelson, Catherine
Nixon, Rebecca
O'Donnell, Renee
Pechter, Stacy
Persell, Alyssa
Persell, Katie
Persell, Mindy
Persell, Tom
Sloane, Robert
Strauss, Becca
Townsend, Michelle
Usmael, Eftu

Hemophilia Treatment Centers (Tri-State Area)

Children's Minnesota—Center for Bleeding and Clotting Disorders
2530 Chicago Ave S, Suite 175
Minneapolis, MN 55404
612-813-5940

Susan Kearney, MD, Medical Director
Elizabeth Boegeman, LGSW, Social Worker
Latrice Daniel, CPhT, HTC Pharmacy Technician
Kate Garland, MD, Physician
Amy Goldstein, APRN, CNP, DNP, Nurse Practitioner
Sarah Hanson, Physical Therapist, DPT
Nicole Hart, RN, MS, Nurse Coordinator
Ali Kolste, Clinical Research Coordinator
Susan Kuldanek, MD, Physician
Rachel LaQuere, RDN, LD, Dietitian
Stephanie Fritch Lilla, MD, Physician
Jennifer Lissick, PharmD, BCPS, Pharmacist
Shirley Molitor-Kirsch, APRN, CNP
Justin Nelson, MHA, CPhT, Director of Ambulatory Services
Skye Peltier, PA-C, MPH, Physician Assistant
Victoria Peter, RN, Nurse Coordinator
Sue Purdie, RN, BSN, HTC Nurse Coordinator
Rachel Saunders, MS, CGC, Genetic Counselor
Becca Shaheen, HTC Program Coordinator
Michael Sprehe, MD, MPH, Physician
Cecily Wegmann, APRN, CNP, DNP

Mayo Comprehensive Hemophilia Center
Mayo Clinic
Mayo Building 10-55E
200 First Street SW
Rochester, MN 55905
507-284-8634 or 1-800-344-7726

Rajiv Pruthi, MBBS, Medical Director (Adult)
Ahmad Al-Huniti, M.D. Associate Director (Pediatrics)
Aneel Ashrani, MD, MS
Darrin Christopherson, M.B.A., 340 Program Manager
Renata Ducharme, Secretary
Amy Eckerman, RN
Asmaa Ferdjallah, MD, MPH
Ashley Heil, Pharm.D., R.Ph.
Daniel Hilliker, Psychologist
C. Christopher Hook MD
Dawn Inman, RN
Alexis Kuhn, Pharm. D, RPh
Emily McTate, Psychologist
William Nichols, MD
Amy Olson-Treptow, Research Coordinator
Melinda Otto, LSW
Tiffany Plowman, L.P.N., Research Coordinator
Dawn Rusk, RN

M Health Fairview Center for Bleeding and Clotting Disorders
2512 South 7th St, Ste 105
Minneapolis, MN 55454
612-273-5005

Mark Reding, MD—Medical Director
Helen McIntyre, MBA, FACHE Vice President, Operations
Kim Baumann, PT, MPT, Physical Therapist
Lucy Bernhoft-Bediako, PA-C, Physician Assistant
Ashley Buxton, Intake Coordinator
Ricky Chan, PA-C, Physician Assistant
Julia Colling, PA-C, Physician Assistant
Susan Curoe, RN, MS, Nurse Clinician
Jill Gilbertson, Intake Coordinator
Nikki Greene, Pharmacy Coordinator
Hillary Handler, Genetic Counselor
Vicky Hannemann, RN, BSN, Nurse Clinician
Maggie Herrity, RN, Nurse Clinician
Jenny Lesnar, CPhT, Lead Pharmacy Coordinator
Amy Marquez, BS, CPhT, Operations Manager
Marshall Mazepa, MD, Physician
Alex McKeever, Intake Coordinator Supervisor
Michael Nolan, Research Strategist
Skye Peltier, PA-C, Physician Assistant
Dana Smith, Pharmacist
Erica Staub, RN, Nurse Clinician
Amy Wilson, MSW, LICSW, ACM, Social Worker

Sanford Health, Sioux Falls, SD Region
South Dakota Center for Bleeding Disorders
1600 West 22nd Street
P.O. Box 5039
Sioux Falls, SD 57117
605-312-1000 or 800-850-0064

Brianna Murphy, DO
Ashlee Blumhoff, CNP
Amanda Gerber, RN
Paige Lange, Mental Health Counselor
Catherine Nelson, MD
Dan Steventon, PT
Kimberly Van Iperen, RN, Research Nurse
KayeLyn Wagner, MD

HFMD
HEMOPHILIA FOUNDATION OF MINNESOTA/DAKOTAS